Enhertu Availability in Canada
Enhertu (trastuzumab deruxtecan) is FDA-approved in the United States for multiple HER2-expressing malignancies, but the evidence provided does not contain specific information about its regulatory approval status or commercial availability in Canada. 1
Current FDA Approval Status
Enhertu has received FDA approval in the United States for the following indications 1:
- HER2-positive metastatic breast cancer after prior anti-HER2 therapy
- HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-) after prior chemotherapy in the metastatic setting
- HR-positive, HER2-low or HER2-ultralow breast cancer after one or more endocrine therapies
- HER2-mutant NSCLC after prior systemic therapy (accelerated approval)
- HER2-positive gastric/GEJ adenocarcinoma after prior trastuzumab-based regimen
- HER2-positive (IHC 3+) solid tumors with no satisfactory alternatives (accelerated approval)
Clinical Guideline Recognition
ASCO guidelines from 2022 reference trastuzumab deruxtecan (T-Dxd) as an established treatment option for HER2-positive advanced breast cancer and brain metastases, indicating its integration into standard treatment algorithms 2, 3.
What You Need to Know
To determine Enhertu's availability in Canada, you should:
- Check Health Canada's Drug Product Database for regulatory approval status
- Contact the manufacturer (Daiichi Sankyo/AstraZeneca) directly for Canadian distribution information
- Verify provincial formulary coverage as approval and reimbursement are separate processes in Canada
- Consider compassionate access programs if the drug is approved but not yet widely available
The drug has demonstrated robust efficacy across multiple tumor types with objective response rates of 55-60% in HER2-positive breast cancer 4, 5, though interstitial lung disease remains a critical safety concern requiring vigilant monitoring in 10-15% of patients 5.